Alpha Teknova (TKNO) opened Q1 2026 with revenue of US$11.1 million and a loss of US$4.6 million, translating to basic EPS of US$0.08 loss as the company continued to invest ahead of profitability. Over recent quarters, revenue has moved from US$9.8 million in Q1 2025 and US$9.3 million in Q4 2024 to the latest US$11.1 million. Basic EPS has stayed in a tight band around a US$0.08 to US$0.11 loss, indicating that the focus remains on scaling revenue rather than delivering positive earnings. For investors, the key consideration is how growth expectations and a cited valuation gap compare with ongoing losses and compressed margins.

See our full analysis for Alpha Teknova.

With the numbers on the table, the next step is to see how this latest quarter lines up against the most common narratives around Alpha Teknova’s growth potential, risks, and long term earnings power.

Q1 loss of US$4.6 million keeps margins in the red

• Net income for Q1 2026 was a loss of US$4.6 million, compared with losses between US$3.6 million and US$5.7 million across the previous five quarters, and trailing 12 month losses sit at US$17.2 million on US$41.8 million of revenue.
• Bears argue that persistent losses and negative operating margins limit flexibility, and the data does line up with that concern:
  • Trailing 12 month EPS is a loss of US$0.32 per share, close to the prior period loss of US$0.32, which fits the bearish view that profitability is not improving quickly.
  • Analysts in the cautious camp also point to forecasts that the company will remain unprofitable for at least three years, which is consistent with the current run rate of losses over the trailing 12 months.

On this view, skeptics see the current loss profile as a real execution hurdle rather than just a temporary blip. They focus on how long it may take for margins to reach sustainable levels before the stock can support a stronger valuation narrative. 🐻 Alpha Teknova Bear Case

Revenue around US$42 million backs a 14.5% growth story

• Over the trailing 12 months, revenue totals US$41.8 million compared with US$37.7 million a year earlier in the dataset, and forecasts in the supplied data call for about 14.5% annual revenue growth going forward.
• Bulls highlight this forecast growth as the core of their thesis, and the recent numbers give them some support:
  • Q1 2026 revenue of US$11.1 million is higher than any quarter in the last six reported, which fits the optimistic view that the business is scaling its top line.
  • The bullish narrative leans on this trend to argue that a larger revenue base could eventually help absorb fixed costs, even though analysts still do not expect profitability within the next three years.

For readers following the growth angle, this combination of a roughly US$42 million trailing revenue base and a 14.5% annual growth forecast is a key factor that bullish investors are watching to assess whether the long term story stays on track. 🐂 Alpha Teknova Bull Case

P/S of 5.1x and DCF fair value of US$15.76 highlight valuation tension

• At a share price of US$4.00, the stock trades on a P/S of 5.1x versus a peer average of 2.2x and a US Life Sciences industry average of 3.4x, while the supplied DCF fair value is US$15.76, which is materially higher than the current price.
• Consensus narrative watchers have to balance a premium P/S against that DCF fair value gap:
  • Analysts in the balanced view group also cite a US$9.00 price target, which sits between the current market price and the DCF fair value, reflecting mixed views on how quickly losses might narrow.
  • At the same time, the data notes above market share price volatility over the last three months, so any gap between P/S multiples and intrinsic value estimates may take time and stable execution before it narrows.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alpha Teknova on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages or a balanced setup, the combination of ongoing losses, growth expectations and valuation signals means you should move quickly to test the data yourself, compare the risks and rewards, and see the full 2 key rewards and 2 important warning signs

See What Else Is Out There

Alpha Teknova is still reporting losses, has negative operating margins, and trades on a higher P/S multiple than peers, which raises valuation risk for investors.

If you are concerned about paying up for ongoing losses, use the 51 high quality undervalued stocks to quickly find stocks where pricing and fundamentals may be better aligned right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.